Evidence-led education. Independently researched. Medically reviewed content clearly labeled.
Live Wellness

GLP-1 fundamentals

How GLP-1 Medications Work

A plain-language guide to appetite, digestion, blood sugar and the differences among incretin medications.

Updated September 14, 2026 9 min read

GLP-1 medicines mimic or amplify hormone signals involved in appetite, digestion and glucose regulation. Different drugs target different receptors and carry different approved uses.

What to know

  • They can reduce appetite and slow stomach emptying.
  • They are tools—not replacements for nutrition, movement and medical follow-up.
  • Benefits and risks depend on the medication and the person.

Start with incretin signaling

GLP-1 is an incretin hormone released after eating. GLP-1 receptor agonists reproduce part of that signal for longer than native GLP-1, increasing glucose-dependent insulin secretion, reducing inappropriate glucagon secretion, and slowing gastric emptying. Those actions help explain effects on glucose, appetite, and fullness.[1,2]

Semaglutide and tirzepatide are not the same mechanism

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. The shared shorthand “GLP-1 medication” is useful for conversation, but it should not erase differences in receptor activity, dose, evidence, or labeling.[2,4]

The brand determines the approved job

The same ingredient can appear in brands with different FDA-approved indications. Ozempic and Mounjaro center on type 2 diabetes; Wegovy and Zepbound include chronic weight-management indications. Current labels also contain product-specific cardiovascular, kidney, liver, adolescent, or sleep-apnea uses. A brand should not inherit another brand’s indication merely because the ingredient matches.[1,2,3,4]

Why appetite and meal size can change

Changes in appetite, earlier fullness, and delayed gastric emptying can reduce energy intake. That is a treatment effect, not a goal to eat as little as possible. Persistent difficulty meeting food or fluid needs deserves clinical attention and may call for a dietitian-supported plan.[5]

Dose escalation is part of tolerability management

These products start below their maintenance doses and escalate according to product-specific schedules. The milligram numbers cannot be converted across different ingredients, and the next increase should follow the prescription rather than a response seen online.[1,2,3,4]

What medication does not replace

Medication does not automatically preserve muscle, build strength, supply protein or micronutrients, or create a maintenance plan. Nutrition support and progressive resistance exercise address different parts of health than appetite pharmacology.[5]

Use a four-question treatment discussion

Ask which exact product and indication are being considered, what outcome will define benefit, which adverse effects or history change the plan, and how treatment will be monitored or stopped. Those questions are more useful than asking which medication is universally “strongest.”

Frequently asked questions

Are all GLP-1 medications the same?

No. Active ingredients, receptor targets, doses, delivery forms and FDA-approved indications differ.

Do GLP-1s permanently change metabolism?

They influence appetite and metabolic regulation while used. Weight regain after stopping is common in trials, so any discontinuation plan should be discussed with a clinician.

Sources

  1. Ozempic prescribing information — U.S. Food and Drug Administration (2026-05)
  2. Wegovy prescribing information — U.S. Food and Drug Administration (2025-12)
  3. Mounjaro prescribing information — U.S. Food and Drug Administration (2026-01)
  4. Zepbound prescribing information — U.S. Food and Drug Administration (2026-02)
  5. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory — American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society (2025-06)

Continue learning